Drugs that contain Vosoritide
1. List of Voxzogo drug patents
VOXZOGO's oppositions filed in EPO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(6 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
Do you want to check out VOXZOGO patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 19, 2026 |
| Orphan Drug Exclusivity (ODE) | Nov 19, 2028 |
NCE-1 date: 2025-11-19
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
More Information on Dosage
VOXZOGO family patents
16
United States
5
Korea, Republic of
4
European Union
3
China
3
Russia
3
Brazil
3
Argentina
3
Japan
3
Israel
2
Spain
2
Hong Kong
2
Denmark
2
Poland
2
Canada
2
Croatia
2
Chile
2
Portugal
2
Taiwan
2
Mexico
2
Australia
2
Hungary
1
Peru
1
South Africa
1
Colombia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic